Ceftobiprole (BioDeep_00000837635)
代谢物信息卡片
Ceftobiprole
化学式: C20H22N8O6S2 (534.1103672)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1CNCC1N2CCC(=CC3=C(N4C(C(C4=O)NC(=O)C(=NO)C5=NSC(=N5)N)SC3)C(=O)O)C2=O
InChI: InChI=1S/C20H22N8O6S2/c21-20-24-14(26-36-20)11(25-34)15(29)23-12-17(31)28-13(19(32)33)9(7-35-18(12)28)5-8-2-4-27(16(8)30)10-1-3-22-6-10/h5,10,12,18,22,34H,1-4,6-7H2,(H,23,29)(H,32,33)(H2,21,24,26)/b8-5+,25-11-/t10-,12-,18-/m1/s1
描述信息
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D002511 - Cephalosporins
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams
D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:140407
- KEGGdrug: D08885
- PubChem: 135413542
- DrugBank: DB04918
- ChEMBL: CHEMBL520642
- CAS: 209467-52-7
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Christopher M Rubino, Mark Polak, Sebastian Schröpf, Hans Georg Münch, Anne Smits, Veerle Cossey, Tomasz Tomasik, Przemko Kwinta, Rima Snariene, Arunas Liubsys, Dace Gardovska, Chi Dang Hornik, Miroslava Bosheva, Christine Ruehle, Karine Litherland, Kamal Hamed. Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients.
The Pediatric infectious disease journal.
2021 11; 40(11):997-1003. doi:
10.1097/inf.0000000000003296. [PMID: 34533489] - Benoit Llopis, Alexandre Bleibtreu, Dimitri Schlemmer, Pascal Robidou, Olivier Paccoud, Nadine Tissot, Gaëlle Noé, Helga Junot, Charles-Édouard Luyt, Christian Funck-Brentano, Noël Zahr. Simple and accurate quantitative analysis of cefiderocol and ceftobiprole in human plasma using liquid chromatography-isotope dilution tandem mass spectrometry: interest for their therapeutic drug monitoring and pharmacokinetic studies.
Clinical chemistry and laboratory medicine.
2021 10; 59(11):1800-1810. doi:
10.1515/cclm-2021-0423. [PMID: 34243226] - Christopher M Rubino, Anthony P Cammarata, Anne Smits, Sebastian Schröpf, Mark Polak, Karine Litherland, Kamal Hamed. Model-Based Approach for Optimizing Ceftobiprole Dosage in Pediatric Patients.
Antimicrobial agents and chemotherapy.
2021 10; 65(11):e0120621. doi:
10.1128/aac.01206-21. [PMID: 34398669] - Emanuele Durante-Mangoni, Roberto Andini, Maria Civita Mazza, Francesco Sangiovanni, Lorenzo Bertolino, Maria Paola Ursi, Laurenza Paradiso, Arta Karruli, Clelia Esposito, Patrizia Murino, Antonio Corcione, Rosa Zampino. Real-life experience with ceftobiprole in a tertiary-care hospital.
Journal of global antimicrobial resistance.
2020 09; 22(?):386-390. doi:
10.1016/j.jgar.2020.03.010. [PMID: 32247081] - J R Azanza Perea, B Sádaba Díaz de Rada. Ceftobiprole: pharmacokinetics and PK/PD profile.
Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia.
2019 Sep; 32 Suppl 3(?):11-16. doi:
NULL. [PMID: 31364336] - Benjamin Lima, Sandra Bodeau, Marie-Charlotte Quinton, Cyril Leven, Anne-Sophie Lemaire-Hurtel, Youssef Bennis. Validation and Application of an HPLC-DAD Method for Routine Therapeutic Drug Monitoring of Ceftobiprole.
Antimicrobial agents and chemotherapy.
2019 07; 63(7):. doi:
10.1128/aac.00515-19. [PMID: 31010863] - A E Muller, N Punt, J W Mouton. Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia.
Antimicrobial agents and chemotherapy.
2014 May; 58(5):2512-9. doi:
10.1128/aac.02611-13. [PMID: 24514085] - April M Barbour, Stephan Schmidt, Luning Zhuang, Kenneth Rand, Hartmut Derendorf. Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches.
International journal of antimicrobial agents.
2014 Jan; 43(1):60-7. doi:
10.1016/j.ijantimicag.2013.08.016. [PMID: 24183800] - Darren Abbanat, Wenchi Shang, Karen Amsler, Colleen Santoro, Ellen Baum, Steven Crespo-Carbone, A Simon Lynch. Evaluation of the in vitro activities of ceftobiprole and comparators in staphylococcal colony or microtitre plate biofilm assays.
International journal of antimicrobial agents.
2014 Jan; 43(1):32-9. doi:
10.1016/j.ijantimicag.2013.09.013. [PMID: 24252780] - Andrew A Udy, Jason A Roberts, Jan J De Waele, David L Paterson, Jeffrey Lipman. What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance.
International journal of antimicrobial agents.
2012 Jun; 39(6):455-7. doi:
10.1016/j.ijantimicag.2012.02.010. [PMID: 22483562] - Tobias Bäckström, Georgios Panagiotidis, Olof Beck, Charlotte Asker-Hagelberg, Mamun-Ur Rashid, Andrej Weintraub, Carl Erik Nord. Effect of ceftobiprole on the normal human intestinal microflora.
International journal of antimicrobial agents.
2010 Dec; 36(6):537-41. doi:
10.1016/j.ijantimicag.2010.07.021. [PMID: 20926263] - Daniel G Dauner, Robert E Nelson, Donna C Taketa. Ceftobiprole: A novel, broad-spectrum cephalosporin with activity against methicillin-resistant Staphylococcus aureus.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
2010 Jun; 67(12):983-93. doi:
10.2146/ajhp090285. [PMID: 20516468] - Ji-Young Rhee, Young Kyoung Park, Joo Yeon Shin, Ji Young Choi, Mi Young Lee, Kyong Ran Peck, Jae-Hoon Song, Kwan Soo Ko. KPC-producing extreme drug-resistant Klebsiella pneumoniae isolate from a patient with diabetes mellitus and chronic renal failure on hemodialysis in South Korea.
Antimicrobial agents and chemotherapy.
2010 May; 54(5):2278-9. doi:
10.1128/aac.00011-10. [PMID: 20211897] - Keith A Rodvold, David P Nicolau, Thomas P Lodise, Mohammed Khashab, Gary J Noel, James B Kahn, Mark Gotfried, Sara A Murray, Susan Nicholson, Somvadee Laohavaleeson, Pamela R Tessier, G L Drusano. Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.
Antimicrobial agents and chemotherapy.
2009 Aug; 53(8):3294-301. doi:
10.1128/aac.00144-09. [PMID: 19451287] - April Barbour, Stephan Schmidt, Sreedharan Nair Sabarinath, Maria Grant, Christoph Seubert, Donna Skee, Bindu Murthy, Hartmut Derendorf. Soft-tissue penetration of ceftobiprole in healthy volunteers determined by in vivo microdialysis.
Antimicrobial agents and chemotherapy.
2009 Jul; 53(7):2773-6. doi:
10.1128/aac.01409-08. [PMID: 19364847] - April Barbour, Stephan Schmidt, Kenneth H Rand, Hartmut Derendorf. Ceftobiprole: a novel cephalosporin with activity against Gram-positive and Gram-negative pathogens, including methicillin-resistant Staphylococcus aureus (MRSA).
International journal of antimicrobial agents.
2009 Jul; 34(1):1-7. doi:
10.1016/j.ijantimicag.2008.12.012. [PMID: 19261449] - Holly Kimko, Bindu Murthy, Xu Xu, Partha Nandy, Richard Strauss, Gary J Noel. Population pharmacokinetic analysis of ceftobiprole for treatment of complicated skin and skin structure infections.
Antimicrobial agents and chemotherapy.
2009 Mar; 53(3):1228-30. doi:
10.1128/aac.00632-08. [PMID: 19075059] - W A Craig, D R Andes. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models.
Antimicrobial agents and chemotherapy.
2008 Oct; 52(10):3492-6. doi:
10.1128/aac.01273-07. [PMID: 18676887] - Somvadee Laohavaleeson, Pamela R Tessier, David P Nicolau. Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains.
Antimicrobial agents and chemotherapy.
2008 Jul; 52(7):2389-94. doi:
10.1128/aac.01422-07. [PMID: 18411322] - R Scott Obach, Franco Lombardo, Nigel J Waters. Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Drug metabolism and disposition: the biological fate of chemicals.
2008 Jul; 36(7):1385-405. doi:
10.1124/dmd.108.020479. [PMID: 18426954] - Li-Yan Yin, Jason H Calhoun, Jacob K Thomas, Stuart Shapiro, Anne Schmitt-Hoffmann. Efficacies of ceftobiprole medocaril and comparators in a rabbit model of osteomyelitis due to methicillin-resistant Staphylococcus aureus.
Antimicrobial agents and chemotherapy.
2008 May; 52(5):1618-22. doi:
10.1128/aac.00638-07. [PMID: 18332175] - George G Zhanel, Ashley Lam, Frank Schweizer, Kristjan Thomson, Andrew Walkty, Ethan Rubinstein, Alfred S Gin, Daryl J Hoban, Ayman M Noreddin, James A Karlowsky. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
American journal of clinical dermatology.
2008; 9(4):245-54. doi:
10.2165/00128071-200809040-00004. [PMID: 18572975] - Anne Schmitt-Hoffmann, Lars Nyman, Brigitte Roos, Michael Schleimer, Jill Sauer, Norman Nashed, Thomas Brown, Anthony Man, Erhard Weidekamm. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.
Antimicrobial agents and chemotherapy.
2004 Jul; 48(7):2576-80. doi:
10.1128/aac.48.7.2576-2580.2004. [PMID: 15215111] - Anne Schmitt-Hoffmann, Brigitte Roos, Michael Schleimer, Jill Sauer, Anthony Man, Norman Nashed, Thomas Brown, Antonio Perez, Erhard Weidekamm, Péter Kovács. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers.
Antimicrobial agents and chemotherapy.
2004 Jul; 48(7):2570-5. doi:
10.1128/aac.48.7.2570-2575.2004. [PMID: 15215110] - Johan W Mouton, Anne Schmitt-Hoffmann, Stuart Shapiro, Norman Nashed, Nieko C Punt. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141.
Antimicrobial agents and chemotherapy.
2004 May; 48(5):1713-8. doi:
10.1128/aac.48.5.1713-1718.2004. [PMID: 15105125] - E Azoulay-Dupuis, J P Bédos, J Mohler, A Schmitt-Hoffmann, M Schleimer, S Shapiro. Efficacy of BAL5788, a prodrug of cephalosporin BAL9141, in a mouse model of acute pneumococcal pneumonia.
Antimicrobial agents and chemotherapy.
2004 Apr; 48(4):1105-11. doi:
10.1128/aac.48.4.1105-1111.2004. [PMID: 15047508]